Pembrolizumab for refractory primary mediastinal B-cell lymphoma with central nervous system involvement.
Hematol Oncol
; 39(3): 419-422, 2021 Aug.
Article
em En
| MEDLINE
| ID: mdl-33369766
ABSTRACT
Primary mediastinal large B-cell lymphoma (PMBCL) is a rare aggressive B-cell lymphoma characterized by the frequent presence of amplification and translocation events at 9p24.1, resulting in the expression of the programmed cell death-1 (PD-1) ligands PD-L1 and PD-L2. Pembrolizumab, a humanized anti-PD-1 monoclonal antibody, binds PD-1 and blocks this interaction, enhancing the activity of the immune system against tumor cells, and has shown activity in PMBCL and in some cases of primary and secondary central nervous system (CNS) lymphoma. We report the case of a 40-year-old woman diagnosed with relapsed PMBCL and secondary CNS involvement who responded to pembrolizumab monotherapy, allowing for a later allogeneic stem cell transplant.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Linfoma de Células B
/
Neoplasias do Sistema Nervoso Central
/
Transplante de Células-Tronco
/
Anticorpos Monoclonais Humanizados
/
Neoplasias do Mediastino
Limite:
Adult
/
Female
/
Humans
Idioma:
En
Revista:
Hematol Oncol
Ano de publicação:
2021
Tipo de documento:
Article
País de afiliação:
Espanha